Healthcare / Medical Instruments & SuppliesTaiwan
$54.50
-0.30 (-0.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $235.0M · quality 71.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.1B
P/E
25.0x
↑EV/EBITDA
13.6x
↑ROE
8.2%
↑Gross Margin
72.0%
↑Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.7%
FCF CAGR
-48.9%
FCF margin
2.5%
FCF / Net income
0.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $886.6M · net income $162.3M · FCF $22.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $886.6M | $886.6M | $883.3M | $713.0M | $557.3M |
| Net Income | $162.3M | $162.3M | $242.3M | $177.9M | $141.7M |
| EBITDA | $273.4M | $273.4M | $362.5M | $281.3M | $242.1M |
| EPS | — | — | 3.30 | 2.41 | 1.92 |
| Gross Margin | 72.0% | 72.0% | 74.2% | 71.9% | 66.7% |
| Operating Margin | 21.4% | 21.4% | 28.1% | 28.0% | 24.2% |
| Net Margin | 18.3% | 18.3% | 27.4% | 25.0% | 25.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 0.12 | 0.21 | 0.28 |
| Current Ratio | 4.09 | 4.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $22.2M | $22.2M | $235.0M | $257.2M | $167.0M |
| Returns | |||||
| ROE | 8.2% | 8.2% | 12.8% | 10.9% | 9.4% |
| Valuation | |||||
| P/E | 25.00 | 25.00 | 32.12 | 31.58 | 28.70 |
| EV/EBITDA | 13.60 | 13.60 | 20.45 | 20.10 | 16.29 |
| P/B | 2.06 | 2.06 | 4.16 | 3.58 | 2.72 |
| Growth & Yield | |||||
| Revenue Growth | 0.4% | 0.4% | 23.9% | 27.9% | — |
| EPS Growth | — | — | 36.9% | 25.5% | — |
| Dividend Yield | 3.5% | 3.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-39.3%
Start / end P/E
n/dx → n/dx
EPS bridge
3.30 → n/d
Residual
-42.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.